Effect of C-reactive protein reduction on paroxysmal atrial fibrillation

American Heart Journal

Volumn 150, Issue 5, 2005, Pages 1064.e7-1064.e12

  Dernellis, John ^a,b   Panaretou, Maria ^a  

^a Vostanion Hospital   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; PLACEBO;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 27744531655     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.06.032     Document Type: Article

References (31)

1. J. Dernellis, and M. Panaretou C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation Acta Cardiol 56 2001 375 380
2. R.J. Aviles, D.O. Martin, and C. Apperson-Hansen Inflammation as a risk factor for atrial fibrillation Circulation 108 2003 3006 3010
3. C.W. Siu, C.P. Lau, and H.F. Tse Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion Am J Cardiol 92 2003 1343 1345
4. J. Dernellis, and M. Panaretou Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation Eur Heart J 25 2004 1100 1107
5. Y. Young-Xu, S. Jabbour, and R. Goldberg Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease Am J Cardiol 92 2003 1379 1383
6. R.H. Abdelhadi, M.K. Chung, and D.R. Van Wagoner New hope for the prevention of recurrent atrial fibrillation Eur Heart J 25 2004 1089 1090
7. S. Niwano, Y. Wakisaka, and J. Kojima Monitoring the progression of the atrial electrical remodeling in patients with paroxysmal atrial fibrillation Circ J 67 2003 133 138
8. P. Bruins, H. Velthius, and A.P. Yazdanbakhsh Activation of the complement system during and after cardiopulmonary bypass surgery. Post-surgery activation involves C-reactive protein and is associated with postoperative arrhythmia Circulation 96 1997 3542 3548
9. M.H. Kaplan, and J.E. Volanakis Interaction of C-reactive protein complexes with the complement system J Immunol 6 1974 2135 2147
10. J.E. Volanakis, and K.W.A. Wirtz Interaction of C-reactive protein with artificial phosphatidylcholine bilayers Nature 281 1979 155 157
11. J. Wu, and P.B. Corr Influence of long chain acylcarnitines on the voltage-dependent calcium current in adult ventricular myocytes Am J Physiol 263 1992 H410 H417
12. S. Baudner, and F. Dati Standardisierung der Bestimmung von 14 Proteinen in Human-Serum auf der Basis des neuen IFCC/BCR/CAP Internationalen Referenzmaterials CRM 470 J Lab Med 20 1996 145 152
13. F.D. Murgatroyd, B. Xie, and X. Copie Identification of atrial fibrillation episodes in ambulatory electrocardiographic recordings: validation of a method for obtaining labelled RR interval files Pacing Clin Electrophysiol 18 1995 1315 1320
14. J. Godtfredsen Atrial fibrillation: course and prognosis: a follow-up study of 1212 cases H.E. Kulbertus S.B. Olsson M. Schlepper Atrial fibrillation 1982 AB Hassle Molndal, Sweden 134 145
15. N. Takahashi, A. Seki, and K. Imataka Clinical features of paroxysmal atrial fibrillation: an observation of 94 patients Jpn Heart J 22 1981 143 149
16. V. Fuster, L. Ryden, and R. Asinger ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Circulation 104 2001 2118 2150
17. D. Jabaudon, J. Sztajzel, and K. Sievert Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack Stroke 35 2004 1647 1651
18. R.L. Page, W.E. Wilkinson, and W.K. Clair Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia Circulation 89 1994 224 227
19. A. Schuchert, G. Behrens, and T. Meinertz Impact of long-term ECG recording on the detection of paroxysmal atrial fibrillation in patients after an acute ischemic stroke Pacing Clin Electrophysiol 22 1999 1082 1084
20. J.S. Steinberg, A. Sadaniantz, and J. Kron Analysis of cause-specific mortality in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study Circulation 109 2004 1973 1980
21. S.D. Corley, A.E. Epstein, and J.P. DiMarco Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study Circulation 109 2004 1509 1513
22. R. Wolk, P. Kulakowski, and S. Karczmarewicz The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone Int J Cardiol 54 1996 207 211
23. P.M. Ridker, M. Cushman, and M.J. Stampfer Inflammation, aspirin and risk of cardiovascular disease in apparently healthy men N Engl J Med 336 1997 973 979
24. M. Chung, D. Martin, and D. Sprecher C-reactive protein elevation in patients with atrial arrhythmias. Inflammatory mechanisms and persistence of atrial fibrillation Circulation 104 2001 2886 2891
25. P.M. Ridker, C.P. Cannon, and D. Morrow C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
26. J.L. Anderson, C.A. Allen Maycock, and D.L. Lappe Frequency of elevation of C-reactive protein in atrial fibrillation Am J Cardiol 94 2004 1255 1259
27. K. Kumagai, H. Nakashima, and K. Saku The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model Cardiovasc Res 62 2004 105 111
28. P.M. Ridker, M. Cushman, and M.J. Stampfer Inflammation, aspirin and risk of cardiovascular disease in apparently healthy men N Engl J Med 336 1997 973 979
29. S. Cardin, D. Li, and N. Thorin-Trescases Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways Cardiovasc Res 60 2003 315 325
30. J.S. Healey, C.A. Morillo, and S.J. Connolly Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling Curr Opin Cardiol 20 2005 31 37
31. A.P. Maggioni, R. Latini, and P.E. Carson Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT) Am Heart J 149 2005 548 557